Role of Beta-Adrenergic Receptor Gene Polymorphisms in the Long-Term Effects of Beta-Blockade with Carvedilol in Patients with Chronic Heart Failure
- 1 February 2010
- journal article
- clinical trial
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 24 (1) , 49-60
Abstract
Beta-blockers are mainstay of current treatment of heart failure (HF). Beta-adrenergic receptors (AR) single nucleotide gene polymorphisms (SNPs) may influence the sensitivity and density of beta-AR. We assessed the relation between three common beta-AR SNPs and the response to carvedilol administration. We studied 183 consecutive patients with chronic HF due to ischemic or nonischemic cardiomyopathy, a LV ejection fraction (LVEF) ≤ 0.35, not previously treated with beta-blockers. Each patient underwent gated-SPECT radionuclide ventriculography, cardiopulmonary exercise testing and invasive hemodynamic monitoring at baseline and after 12 months of carvedilol administration at maintenance dosages. The beta1-AR gene Arg389Gly and the beta2-AR gene Arg16Gly SNPs were not related to the response to carvedilol administration. Homozygotes for the Glu27Glu allele showed a greater increase in the LVEF, compared to the other patients (+13.0 ± 12.2% versus +7.1 ± 8.1% in the Gln27Gln homozygotes, and 8.3 ± 11.4% units in the Gln27Glu heterozygotes; p = 0.022 by ANOVA). Glu27Glu homozygotes also showed a greater decline in the pulmonary wedge pressure both at rest and at peak exercise. Gln27Glu SNP was selected amongst the determinants of the LVEF response to carvedilol at multivariable analysis, in addition to the cause of cardiomyopathy, baseline systolic blood pressure and the dose of carvedilol administered. Beta1-AR Arg389Gly and beta2-AR Arg16Gly SNPs are not related to the response to carvedilol therapy. In contrast, the Gln27Glu SNP is a determinant of the LVEF response to this agent in patients with chronic HF.Keywords
This publication has 37 references indexed in Scilit:
- An α 2C -Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the β-Blocker Bucindolol in Chronic Heart FailureCirculation: Heart Failure, 2010
- Pharmacogenomics and the Failing Heart: Are We Waiting for Godot?JACC, 2008
- Arg389Gly-β1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilolPharmacogenetics and Genomics, 2007
- The effects of β-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosisAmerican Heart Journal, 2007
- Synergistic polymorphisms of β1 and α2C-adrenergic receptors and the influence on left ventricular ejection fraction response to β-blocker therapy in heart failurePharmacogenetics and Genomics, 2007
- A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failureProceedings of the National Academy of Sciences, 2006
- The Polymorphonuclear Leukocyte and the Abdominal Aortic AneurysmCirculation, 2005
- ??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapyPharmacogenetics and Genomics, 2005
- Relation between contractile reserve and improvement in left ventricular function with beta-blocker therapy in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathyThe American Journal of Cardiology, 2004
- The Effect of Common Polymorphisms of the β2-Adrenergic Receptor on Agonist-Mediated Vascular DesensitizationNew England Journal of Medicine, 2001